A Phase 3 interventional study of Celecoxib and Placebo in Adenomatous Polyposis Coli, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 43 sites in 14 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.
Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2006, is one of 3 in phase 3, and was the 5th registered.
92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.
Browse Adenomatous Polyposis Coli studies →12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
HonorHealth Research Institute · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Rapamycin Holdings Inc. · Sites in United States, Denmark, Germany and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 3
First in 2001; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 40 across 61 interventional studies indexed under Adenomatous Polyposis Coli.
Median enrollment 42 across the 27 interventional studies, 833 across the 12 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Adenomatous Polyposis Coli — fewer than ten, so there is no comparison to draw.
6 of the studies in Adenomatous Polyposis Coli with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04678011Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy | 2026-11 |
| NCT04677998Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis | 2026-11 |
| NCT05919264Parabilis Medicines, Inc.FOG-001 in Locally Advanced or Metastatic Solid Tumors | 2027-04-01 |
| NCT05552755Recursion Pharmaceuticals Inc.Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | 2027-06 |
| NCT06557733National Cancer Institute (NCI)An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).
Per DMC recommendation, the study was terminated early (31Oct2013) due to low enrollment and low endpoint accumulation rate. No safety concerns were involved in the decision to terminate the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
celecoxib, 16 mg/kg/day, for 5 years
Drug: Celecoxib
Masked, placebo comparator
Drug: Placebo
celecoxib, 16 mg/kg/day, for 5 years
Also known as: celebrex, SC-58635
Masked, placebo comparator
Time to Disease Progression
Time to disease progression was defined as the time from randomization to the earliest occurrence of one or more of the following events: 1. Appearance of ≥20 polyps (\>2 mm in size) at any colonoscopy during the study (Polyps); or 2. Diagnosis of colorectal malignancy (ColMal).
Time frame: 5 years
Time to Treatment Failure
Time to treatment failure was defined as time from randomization to the earliest occurrence of one or more of the following: * Appearance of ≥20 polyps (\>2 mm in size) at any colonoscopy during the study (Polyps), or * Diagnosis of colorectal malignancy (ColMal), or * Treatment related dropout (DO). The treatment related dropout was defined as insufficient clinical response, progression of disease, death, adverse event, treatment-related laboratory abnormality, subject no longer willing to participate in study, and other reasons that might be related to treatment as determined by treating physicians in a blind fashion before database release.
Time frame: 5 years
Total Number of Colorectal Polyps
Total number of colorectal polyps \>2 mm in size, that were detected over Years 1 - 5 cumulatively. Weighted total number of colorectal polyps over Years 1 - 5 cumulatively was defined as the total number of colorectal polyps \>2 mm in size, that were detected over Years 1 - 5, divided by the number of colonoscopies that the participant had during the study.
Time frame: Years 1 - 5
Colorectal Polyp Burden
The polyp burden was defined as the sum of the largest diameters of all polyps (\>2 mm in size) over Years 1 - 5 cumulatively. Weighted colorectal polyp burden over Years 1 - 5 cumulatively was defined as the polyp burden over Years 1 - 5 divided by the number of colonoscopies that the participant had during the study.
Time frame: Years 1 - 5
A total of 305 participants were screened, whereof 106 were randomized into the study, and of whom 101 took at least 1 dose of study drug. The clinical study was conducted in 18 centers across 13 countries: Belgium, Czech Republic, Hong Kong, Hungary, Israel, Italy, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom, and United States.
| Milestone | Celecoxib | Placebo |
|---|---|---|
| Started | 55 | 51 |
| Treated | 53 | 48 |
| Completed | 4 | 7 |
| Not completed | 51 | 44 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Lack of efficacy | 6 | 11 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Reason not specified | 2 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 |
| Withdrew: Study terminated by the sponsor | 34 | 31 |
Time to disease progression was defined as the time from randomization to the earliest occurrence of one or more of the following events: 1. Appearance of ≥20 polyps (\>2 mm in size) at any colonoscopy during the study (Polyps); or 2. Diagnosis of colorectal malignancy (ColMal).
| years | Celecoxib | Placebo |
|---|---|---|
| Time to Disease Progression | 2.2 ± 1.08 | 1.8 ± 1.30 |
Time to treatment failure was defined as time from randomization to the earliest occurrence of one or more of the following: * Appearance of ≥20 polyps (\>2 mm in size) at any colonoscopy during the study (Polyps), or * Diagnosis of colorectal malignancy (ColMal), or * Treatment related dropout (DO). The treatment related dropout was defined as insufficient clinical response, progression of disease, death, adverse event, treatment-related laboratory abnormality, subject no longer willing to participate in study, and other reasons that might be related to treatment as determined by treating physicians in a blind fashion before database release.
| years | Celecoxib | Placebo |
|---|---|---|
| Time to Treatment Failure | 2.0 ± 1.12 | 1.7 ± 1.30 |
Total number of colorectal polyps \>2 mm in size, that were detected over Years 1 - 5 cumulatively. Weighted total number of colorectal polyps over Years 1 - 5 cumulatively was defined as the total number of colorectal polyps \>2 mm in size, that were detected over Years 1 - 5, divided by the number of colonoscopies that the participant had during the study.
| polyps | Celecoxib | Placebo |
|---|---|---|
| Year 1 (N: 27, 30) | 3.0 ± 2.68 | 8.1 ± 7.32 |
| Year 2 (N: 21, 25) | 8.8 ± 6.63 | 13.7 ± 10.51 |
| Year 3 (N: 16, 14) | 13.4 ± 11.31 | 22.3 ± 11.74 |
| Year 4 (N: 8, 7) | 18.6 ± 17.65 | 36.4 ± 22.50 |
| Year 5 (N: 2, 2) | 30.5 ± 21.92 | 46.5 ± 34.65 |
| Years 1 - 5 cumulatively (N: 33, 36) | 4.3 ± 3.58 | 8.6 ± 7.12 |
The polyp burden was defined as the sum of the largest diameters of all polyps (\>2 mm in size) over Years 1 - 5 cumulatively. Weighted colorectal polyp burden over Years 1 - 5 cumulatively was defined as the polyp burden over Years 1 - 5 divided by the number of colonoscopies that the participant had during the study.
| mm | Celecoxib | Placebo |
|---|---|---|
| Year 1 (N: 27, 30) | 4.0 ± 1.97 | 4.2 ± 2.05 |
| Year 2 (N: 21, 25) | 6.9 ± 2.28 | 8.1 ± 4.06 |
| Year 3 (N: 16, 14) | 9.6 ± 3.14 | 11.6 ± 4.05 |
| Year 4 (N: 8, 7) | 12.9 ± 3.31 | 18.7 ± 5.88 |
| Year 5 (N: 2, 2) | 20.0 ± 7.07 | 20.0 ± 4.24 |
| Year 1 - 5 cumulatively (N: 33, 36) | 4.1 ± 1.68 | 4.3 ± 1.61 |
Collected over Events were reported from randomization through and including 30 calendar days after the last administration of the study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib | — | 3/53 (5.7%) | 36/53 (67.9%) |
| Placebo | — | 0/48 (0%) | 30/48 (62.5%) |
| Event | Celecoxib | Placebo |
|---|---|---|
| Periorbital cellulitisInfections and infestations | 1/53 | 0/48 |
| PneumoniaInfections and infestations | 1/53 | 0/48 |
| DepressionPsychiatric disorders | 1/53 | 0/48 |
| Event | Celecoxib | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 16/53 | 14/48 |
| Abdominal painGastrointestinal disorders | 9/53 | 10/48 |
| VomitingGastrointestinal disorders | 9/53 | 9/48 |
| Upper respiratory tract infectionInfections and infestations | 4/53 | 9/48 |
| Abdominal discomfortGastrointestinal disorders | 9/53 | 4/48 |
| NauseaGastrointestinal disorders | 8/53 | 8/48 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/53 | 6/48 |
| DiarrhoeaGastrointestinal disorders | 6/53 | 4/48 |
| FatigueGeneral disorders | 6/53 | 4/48 |
| InfluenzaInfections and infestations | 6/53 | 1/48 |
The intent-to-treat (ITT) population (N: 106) consisted of all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether the participants received any study drug or received a different drug from that to which they were randomized.
| Age, Continuous(years) | Celecoxib | Placebo | Total |
|---|---|---|---|
| Mean | 12.6 ± 2.2 | 12.2 ± 1.8 | 12.4 ± 2.0 |
| Sex: Female, Male(Participants) | Celecoxib | Placebo | Total |
|---|---|---|---|
| Female | 29 | 28 | 57 |
| Male | 26 | 23 | 49 |
The record gives a start of Sep 2006, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →